Target intelligence / Profile preview

Discs large MAGUK scaffold protein 3 (DLG3)

Target
DLG3
Molecular classification
Scaffold protein, Membrane-associated guanylate kinase (MAGUK) family, PDZ domain-containing protein, SH3 domain-containing protein
01

Overview

Discs large MAGUK scaffold protein 3 (DLG3, also known as SAP102) is a member of the membrane-associated guanylate kinase (MAGUK) family of scaffold proteins. It contains PDZ, SH3, and inactive guanylate kinase domains arranged in tandem, which together create a supramodule critical for the clustering of membrane receptors (notably NMDA receptors) and organization of cell junctions in neurons and epithelial tissues. DLG3 mediates signal transduction, regulation of cell polarity, and intracellular trafficking of signaling complexes. In cancer biology, it acts as a tumor suppressor in some contexts (notably in glioblastoma and through inhibition of migration, proliferation, and epithelial-mesenchymal transition in breast cancer). It also plays a role in modulating the tumor immune microenvironment, particularly influencing the polarization and activity of tumor-associated macrophages. While associated with sensitivity to chemotherapeutics, DLG3 is not itself a therapeutic drug target or receptor.

Other names
SAP102Neuroendocrine-dlg (NEDLG)Discs large homolog 3 (DLG3)
02

Mechanism of action

Not directly targeted by drugs; functions as a scaffold regulating membrane receptor localization and downstream pathways (e.g., its downregulation leads to PI3K/AKT pathway activation in breast cancer).

03

Biological functions

Cell polarity regulationClustering of NMDA-type glutamate receptors at synaptic sitesRegulation of cell-cell adhesionSignal transductionMaintenance of tissue morphogenesisIntracellular scaffolding for signal complexes
04

Disease associations

Cancer (notably breast cancer and glioblastoma)Neurodevelopmental disorders (mutations associated with X-linked intellectual disability)Immune response modulation (role in immunosuppressive tumor microenvironment, especially M2 macrophage interaction in breast cancer)
05

Safety considerations

Not formally established as a drug target, so no specific drug-based safety concerns known at this time.
06

Interacting drugs

None explicitly identified in the literature as of now; evidence suggests association with sensitivity to certain chemotherapeutic agents in breast and gastric cancer but without named drugs.
07

Biomarkers

DNA methylation status of DLG3 (as a poor prognosis biomarker in breast cancer)Expression levels of DLG3 (potential predictive value for cancer progression and immune cell infiltration)

Beyond the preview

Go deeper on Discs large MAGUK scaffold protein 3 (DLG3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Discs large MAGUK scaffold protein 3 (DLG3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call